Acute myeloid leukemia (AML) is an aggressive blood cancer diagnosed in approximately 120,000 individuals worldwide each year. During treatment for AML, detecting residual disease is essential for prognostication and treatment decision-making. Currently, methods for detecting residual AML are limited to identifying approximately 1:100 to 1:1000 leukemic cells (morphology and DNA sequencing) or are difficult to implement…
By Andrew L. Young, Hannah C. Davis, and Grant A. Challen
About Pairidex
Pairidex® is a team of passionate problem-solvers working to make blood cancer care smarter, faster, and more compassionate. Our expertise spans genomics, oncology, and diagnostics, but it’s our shared dedication to making a real-world difference that sets us apart.